145 related articles for article (PubMed ID: 1651310)
1. Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited.
Rodriguez R; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):859-62; discussion 865. PubMed ID: 1651310
[No Abstract] [Full Text] [Related]
2. [Significance of the combined use of radiosensitizing agents on radiotherapy of malignant encephaloma].
Hoshino T
Rinsho Hoshasen; 1968 Nov; 13(11):885-91. PubMed ID: 4304555
[No Abstract] [Full Text] [Related]
3. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
4. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
Epstein AH; Cook JA; Goffman T; Glatstein E
BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
[No Abstract] [Full Text] [Related]
5. Editorial: Hypoxic cell radiosensitizers.
Belli JA; Hellman S
N Engl J Med; 1976 Jun; 294(25):1399-400. PubMed ID: 177876
[No Abstract] [Full Text] [Related]
6. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
Phillips TL; Levin VA; Ahn DK; Gutin PH; Davis RL; Wilson CB; Prados MD; Wara WM; Flam MS
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):709-14. PubMed ID: 1651306
[TBL] [Abstract][Full Text] [Related]
8. [Results of postoperative treatment of glioblastoma multiforme with a radiation-sensitizing substance (5-bromo-2-deoxyuridine)].
Landolt AM
Acta Neurochir (Wien); 1971; 24(4):263-8. PubMed ID: 4332090
[No Abstract] [Full Text] [Related]
9. [Clinical and experimental results of interstitial Curie-therapy combined with radiosensitizing agents in DS carcinoma of the rat and in infiltrating brain neoplasms].
Mundinger F
Fortschr Geb Rontgenstr Nuklearmed; 1972; ():Suppl:201. PubMed ID: 4341101
[No Abstract] [Full Text] [Related]
10. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
[TBL] [Abstract][Full Text] [Related]
11. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy in the treatment of malignant glioma.
Kim RY; Langford KH; Roth RE
J Med Assoc State Ala; 1977 Oct; 47(4):39-41. PubMed ID: 200689
[No Abstract] [Full Text] [Related]
13. Radiation plus metronidazole for glioblastoma.
Urtasun RC; Band PR; Chapman JD; Feldstein ML
N Engl J Med; 1977 Mar; 296(13):757. PubMed ID: 190541
[No Abstract] [Full Text] [Related]
14. [Effect of BAR therapy in a case of malignant glioma with extracranial metastasis].
Kanno T; Moriyama M; Kagawa M; To T; Ishimori S
No To Shinkei; 1970 Oct; 22(10):1187-91. PubMed ID: 5536188
[No Abstract] [Full Text] [Related]
15. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization of brain tumor cells with a thymidine analogue (bromouridine).
Sano K; Hoshino T; Nagai M
J Neurosurg; 1968 Jun; 28(6):530-8. PubMed ID: 4233585
[No Abstract] [Full Text] [Related]
18. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors.
Phuphanich S; Levin EM; Levin VA
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1769-72. PubMed ID: 6480461
[TBL] [Abstract][Full Text] [Related]
19. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas.
Lambin P; Poortmans P; Menten J; Hamers HP
Radiother Oncol; 1997 Jun; 43(3):324. PubMed ID: 9215796
[No Abstract] [Full Text] [Related]
20. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
